Eintrag weiter verarbeiten
Is the body mass index a predictor of adverse outcome in prostate cancer after radical prostatectomy in a mid‐European study population?
Gespeichert in:
| Zeitschriftentitel: | BJU International |
|---|---|
| Personen und Körperschaften: | , , , , , , , , , |
| In: | BJU International, 103, 2009, 7, S. 877-882 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
Wiley
|
| Schlagwörter: |
| author_facet |
Pfitzenmaier, Jesco Pritsch, Maria Haferkamp, Axel Jakobi, Hildegard Fritsch, Frederik Gilfrich, Christian Djakovic, Nenad Buse, Stephan Pahernik, Sascha Hohenfellner, Markus Pfitzenmaier, Jesco Pritsch, Maria Haferkamp, Axel Jakobi, Hildegard Fritsch, Frederik Gilfrich, Christian Djakovic, Nenad Buse, Stephan Pahernik, Sascha Hohenfellner, Markus |
|---|---|
| author |
Pfitzenmaier, Jesco Pritsch, Maria Haferkamp, Axel Jakobi, Hildegard Fritsch, Frederik Gilfrich, Christian Djakovic, Nenad Buse, Stephan Pahernik, Sascha Hohenfellner, Markus |
| spellingShingle |
Pfitzenmaier, Jesco Pritsch, Maria Haferkamp, Axel Jakobi, Hildegard Fritsch, Frederik Gilfrich, Christian Djakovic, Nenad Buse, Stephan Pahernik, Sascha Hohenfellner, Markus BJU International Is the body mass index a predictor of adverse outcome in prostate cancer after radical prostatectomy in a mid‐European study population? Urology |
| author_sort |
pfitzenmaier, jesco |
| spelling |
Pfitzenmaier, Jesco Pritsch, Maria Haferkamp, Axel Jakobi, Hildegard Fritsch, Frederik Gilfrich, Christian Djakovic, Nenad Buse, Stephan Pahernik, Sascha Hohenfellner, Markus 1464-4096 1464-410X Wiley Urology http://dx.doi.org/10.1111/j.1464-410x.2008.08149.x <jats:sec><jats:title>OBJECTIVES</jats:title><jats:p>To evaluate the effect of body mass index (BMI) on the histopathological and clinical outcome in prostate cancer.</jats:p></jats:sec><jats:sec><jats:title>PATIENTS AND METHODS</jats:title><jats:p>In a prospective urological cancer database, 620 patients with prostate cancer had a radical prostatectomy (RP) as a curative treatment. The patients were categorized into three groups of BMI (kg/m<jats:sup>2</jats:sup>); ≤25.0 (190, ‘normal weight’), >25.0–30.0 (343, ‘overweight’) and >30.0 (87, ‘obese’). We evaluated the histopathological features and the clinical follow‐up after RP. The median (range) age of the men was 64.4 (41.1–80.1) years and the median follow‐up 5.5 (0.1–15.1) years. The preoperative median prostate‐specific antigen (PSA) levels for normal, overweight and obese patients were 9.0 (0.3–133.0), 8.9 (0.4–230.0) and 9.2 (0.5–194.0) ng/mL, respectively.</jats:p></jats:sec><jats:sec><jats:title>RESULTS</jats:title><jats:p>Serum PSA levels were no different among the three groups (<jats:italic>P</jats:italic> = 0.92). The normal, overweight and obese patients had organ‐confined prostate cancer in 53.7%, 57.1% and 58.6%, respectively (<jats:italic>P</jats:italic> = 0.34) and had lymph node metastases in 7.9%, 7.6% and 4.6% (<jats:italic>P</jats:italic> = 0.58). Tumour grading was no different for the three groups (<jats:italic>P</jats:italic> = 0.25). The PSA recurrence‐free, prostate cancer‐specific and overall survival for the three BMI groups did not differ significantly (each <jats:italic>P</jats:italic> > 0.05).</jats:p></jats:sec><jats:sec><jats:title>CONCLUSION</jats:title><jats:p>The BMI cannot be shown to be a predictor of adverse prognosis either for histopathological features or for the clinical outcome, e.g. PSA‐free, prostate cancer‐specific and overall survival, in a mid‐European study population after RP.</jats:p></jats:sec> Is the body mass index a predictor of adverse outcome in prostate cancer after radical prostatectomy in a mid‐European study population? BJU International |
| doi_str_mv |
10.1111/j.1464-410x.2008.08149.x |
| facet_avail |
Online |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTExMS9qLjE0NjQtNDEweC4yMDA4LjA4MTQ5Lng |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTExMS9qLjE0NjQtNDEweC4yMDA4LjA4MTQ5Lng |
| institution |
DE-D275 DE-Bn3 DE-Brt1 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 |
| imprint |
Wiley, 2009 |
| imprint_str_mv |
Wiley, 2009 |
| issn |
1464-410X 1464-4096 |
| issn_str_mv |
1464-410X 1464-4096 |
| language |
English |
| mega_collection |
Wiley (CrossRef) |
| match_str |
pfitzenmaier2009isthebodymassindexapredictorofadverseoutcomeinprostatecancerafterradicalprostatectomyinamideuropeanstudypopulation |
| publishDateSort |
2009 |
| publisher |
Wiley |
| recordtype |
ai |
| record_format |
ai |
| series |
BJU International |
| source_id |
49 |
| title |
Is the body mass index a predictor of adverse outcome in prostate cancer after radical prostatectomy in a mid‐European study population? |
| title_unstemmed |
Is the body mass index a predictor of adverse outcome in prostate cancer after radical prostatectomy in a mid‐European study population? |
| title_full |
Is the body mass index a predictor of adverse outcome in prostate cancer after radical prostatectomy in a mid‐European study population? |
| title_fullStr |
Is the body mass index a predictor of adverse outcome in prostate cancer after radical prostatectomy in a mid‐European study population? |
| title_full_unstemmed |
Is the body mass index a predictor of adverse outcome in prostate cancer after radical prostatectomy in a mid‐European study population? |
| title_short |
Is the body mass index a predictor of adverse outcome in prostate cancer after radical prostatectomy in a mid‐European study population? |
| title_sort |
is the body mass index a predictor of adverse outcome in prostate cancer after radical prostatectomy in a mid‐european study population? |
| topic |
Urology |
| url |
http://dx.doi.org/10.1111/j.1464-410x.2008.08149.x |
| publishDate |
2009 |
| physical |
877-882 |
| description |
<jats:sec><jats:title>OBJECTIVES</jats:title><jats:p>To evaluate the effect of body mass index (BMI) on the histopathological and clinical outcome in prostate cancer.</jats:p></jats:sec><jats:sec><jats:title>PATIENTS AND METHODS</jats:title><jats:p>In a prospective urological cancer database, 620 patients with prostate cancer had a radical prostatectomy (RP) as a curative treatment. The patients were categorized into three groups of BMI (kg/m<jats:sup>2</jats:sup>); ≤25.0 (190, ‘normal weight’), >25.0–30.0 (343, ‘overweight’) and >30.0 (87, ‘obese’). We evaluated the histopathological features and the clinical follow‐up after RP. The median (range) age of the men was 64.4 (41.1–80.1) years and the median follow‐up 5.5 (0.1–15.1) years. The preoperative median prostate‐specific antigen (PSA) levels for normal, overweight and obese patients were 9.0 (0.3–133.0), 8.9 (0.4–230.0) and 9.2 (0.5–194.0) ng/mL, respectively.</jats:p></jats:sec><jats:sec><jats:title>RESULTS</jats:title><jats:p>Serum PSA levels were no different among the three groups (<jats:italic>P</jats:italic> = 0.92). The normal, overweight and obese patients had organ‐confined prostate cancer in 53.7%, 57.1% and 58.6%, respectively (<jats:italic>P</jats:italic> = 0.34) and had lymph node metastases in 7.9%, 7.6% and 4.6% (<jats:italic>P</jats:italic> = 0.58). Tumour grading was no different for the three groups (<jats:italic>P</jats:italic> = 0.25). The PSA recurrence‐free, prostate cancer‐specific and overall survival for the three BMI groups did not differ significantly (each <jats:italic>P</jats:italic> > 0.05).</jats:p></jats:sec><jats:sec><jats:title>CONCLUSION</jats:title><jats:p>The BMI cannot be shown to be a predictor of adverse prognosis either for histopathological features or for the clinical outcome, e.g. PSA‐free, prostate cancer‐specific and overall survival, in a mid‐European study population after RP.</jats:p></jats:sec> |
| container_issue |
7 |
| container_start_page |
877 |
| container_title |
BJU International |
| container_volume |
103 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792343174790774800 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T16:47:30.13Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Is+the+body+mass+index+a+predictor+of+adverse+outcome+in+prostate+cancer+after+radical+prostatectomy+in+a+mid%E2%80%90European+study+population%3F&rft.date=2009-04-01&genre=article&issn=1464-410X&volume=103&issue=7&spage=877&epage=882&pages=877-882&jtitle=BJU+International&atitle=Is+the+body+mass+index+a+predictor+of+adverse+outcome+in+prostate+cancer+after+radical+prostatectomy+in+a+mid%E2%80%90European+study+population%3F&aulast=Hohenfellner&aufirst=Markus&rft_id=info%3Adoi%2F10.1111%2Fj.1464-410x.2008.08149.x&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792343174790774800 |
| author | Pfitzenmaier, Jesco, Pritsch, Maria, Haferkamp, Axel, Jakobi, Hildegard, Fritsch, Frederik, Gilfrich, Christian, Djakovic, Nenad, Buse, Stephan, Pahernik, Sascha, Hohenfellner, Markus |
| author_facet | Pfitzenmaier, Jesco, Pritsch, Maria, Haferkamp, Axel, Jakobi, Hildegard, Fritsch, Frederik, Gilfrich, Christian, Djakovic, Nenad, Buse, Stephan, Pahernik, Sascha, Hohenfellner, Markus, Pfitzenmaier, Jesco, Pritsch, Maria, Haferkamp, Axel, Jakobi, Hildegard, Fritsch, Frederik, Gilfrich, Christian, Djakovic, Nenad, Buse, Stephan, Pahernik, Sascha, Hohenfellner, Markus |
| author_sort | pfitzenmaier, jesco |
| container_issue | 7 |
| container_start_page | 877 |
| container_title | BJU International |
| container_volume | 103 |
| description | <jats:sec><jats:title>OBJECTIVES</jats:title><jats:p>To evaluate the effect of body mass index (BMI) on the histopathological and clinical outcome in prostate cancer.</jats:p></jats:sec><jats:sec><jats:title>PATIENTS AND METHODS</jats:title><jats:p>In a prospective urological cancer database, 620 patients with prostate cancer had a radical prostatectomy (RP) as a curative treatment. The patients were categorized into three groups of BMI (kg/m<jats:sup>2</jats:sup>); ≤25.0 (190, ‘normal weight’), >25.0–30.0 (343, ‘overweight’) and >30.0 (87, ‘obese’). We evaluated the histopathological features and the clinical follow‐up after RP. The median (range) age of the men was 64.4 (41.1–80.1) years and the median follow‐up 5.5 (0.1–15.1) years. The preoperative median prostate‐specific antigen (PSA) levels for normal, overweight and obese patients were 9.0 (0.3–133.0), 8.9 (0.4–230.0) and 9.2 (0.5–194.0) ng/mL, respectively.</jats:p></jats:sec><jats:sec><jats:title>RESULTS</jats:title><jats:p>Serum PSA levels were no different among the three groups (<jats:italic>P</jats:italic> = 0.92). The normal, overweight and obese patients had organ‐confined prostate cancer in 53.7%, 57.1% and 58.6%, respectively (<jats:italic>P</jats:italic> = 0.34) and had lymph node metastases in 7.9%, 7.6% and 4.6% (<jats:italic>P</jats:italic> = 0.58). Tumour grading was no different for the three groups (<jats:italic>P</jats:italic> = 0.25). The PSA recurrence‐free, prostate cancer‐specific and overall survival for the three BMI groups did not differ significantly (each <jats:italic>P</jats:italic> > 0.05).</jats:p></jats:sec><jats:sec><jats:title>CONCLUSION</jats:title><jats:p>The BMI cannot be shown to be a predictor of adverse prognosis either for histopathological features or for the clinical outcome, e.g. PSA‐free, prostate cancer‐specific and overall survival, in a mid‐European study population after RP.</jats:p></jats:sec> |
| doi_str_mv | 10.1111/j.1464-410x.2008.08149.x |
| facet_avail | Online |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTExMS9qLjE0NjQtNDEweC4yMDA4LjA4MTQ5Lng |
| imprint | Wiley, 2009 |
| imprint_str_mv | Wiley, 2009 |
| institution | DE-D275, DE-Bn3, DE-Brt1, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229 |
| issn | 1464-410X, 1464-4096 |
| issn_str_mv | 1464-410X, 1464-4096 |
| language | English |
| last_indexed | 2024-03-01T16:47:30.13Z |
| match_str | pfitzenmaier2009isthebodymassindexapredictorofadverseoutcomeinprostatecancerafterradicalprostatectomyinamideuropeanstudypopulation |
| mega_collection | Wiley (CrossRef) |
| physical | 877-882 |
| publishDate | 2009 |
| publishDateSort | 2009 |
| publisher | Wiley |
| record_format | ai |
| recordtype | ai |
| series | BJU International |
| source_id | 49 |
| spelling | Pfitzenmaier, Jesco Pritsch, Maria Haferkamp, Axel Jakobi, Hildegard Fritsch, Frederik Gilfrich, Christian Djakovic, Nenad Buse, Stephan Pahernik, Sascha Hohenfellner, Markus 1464-4096 1464-410X Wiley Urology http://dx.doi.org/10.1111/j.1464-410x.2008.08149.x <jats:sec><jats:title>OBJECTIVES</jats:title><jats:p>To evaluate the effect of body mass index (BMI) on the histopathological and clinical outcome in prostate cancer.</jats:p></jats:sec><jats:sec><jats:title>PATIENTS AND METHODS</jats:title><jats:p>In a prospective urological cancer database, 620 patients with prostate cancer had a radical prostatectomy (RP) as a curative treatment. The patients were categorized into three groups of BMI (kg/m<jats:sup>2</jats:sup>); ≤25.0 (190, ‘normal weight’), >25.0–30.0 (343, ‘overweight’) and >30.0 (87, ‘obese’). We evaluated the histopathological features and the clinical follow‐up after RP. The median (range) age of the men was 64.4 (41.1–80.1) years and the median follow‐up 5.5 (0.1–15.1) years. The preoperative median prostate‐specific antigen (PSA) levels for normal, overweight and obese patients were 9.0 (0.3–133.0), 8.9 (0.4–230.0) and 9.2 (0.5–194.0) ng/mL, respectively.</jats:p></jats:sec><jats:sec><jats:title>RESULTS</jats:title><jats:p>Serum PSA levels were no different among the three groups (<jats:italic>P</jats:italic> = 0.92). The normal, overweight and obese patients had organ‐confined prostate cancer in 53.7%, 57.1% and 58.6%, respectively (<jats:italic>P</jats:italic> = 0.34) and had lymph node metastases in 7.9%, 7.6% and 4.6% (<jats:italic>P</jats:italic> = 0.58). Tumour grading was no different for the three groups (<jats:italic>P</jats:italic> = 0.25). The PSA recurrence‐free, prostate cancer‐specific and overall survival for the three BMI groups did not differ significantly (each <jats:italic>P</jats:italic> > 0.05).</jats:p></jats:sec><jats:sec><jats:title>CONCLUSION</jats:title><jats:p>The BMI cannot be shown to be a predictor of adverse prognosis either for histopathological features or for the clinical outcome, e.g. PSA‐free, prostate cancer‐specific and overall survival, in a mid‐European study population after RP.</jats:p></jats:sec> Is the body mass index a predictor of adverse outcome in prostate cancer after radical prostatectomy in a mid‐European study population? BJU International |
| spellingShingle | Pfitzenmaier, Jesco, Pritsch, Maria, Haferkamp, Axel, Jakobi, Hildegard, Fritsch, Frederik, Gilfrich, Christian, Djakovic, Nenad, Buse, Stephan, Pahernik, Sascha, Hohenfellner, Markus, BJU International, Is the body mass index a predictor of adverse outcome in prostate cancer after radical prostatectomy in a mid‐European study population?, Urology |
| title | Is the body mass index a predictor of adverse outcome in prostate cancer after radical prostatectomy in a mid‐European study population? |
| title_full | Is the body mass index a predictor of adverse outcome in prostate cancer after radical prostatectomy in a mid‐European study population? |
| title_fullStr | Is the body mass index a predictor of adverse outcome in prostate cancer after radical prostatectomy in a mid‐European study population? |
| title_full_unstemmed | Is the body mass index a predictor of adverse outcome in prostate cancer after radical prostatectomy in a mid‐European study population? |
| title_short | Is the body mass index a predictor of adverse outcome in prostate cancer after radical prostatectomy in a mid‐European study population? |
| title_sort | is the body mass index a predictor of adverse outcome in prostate cancer after radical prostatectomy in a mid‐european study population? |
| title_unstemmed | Is the body mass index a predictor of adverse outcome in prostate cancer after radical prostatectomy in a mid‐European study population? |
| topic | Urology |
| url | http://dx.doi.org/10.1111/j.1464-410x.2008.08149.x |